Compass Pathways is one of the companies spearheading clinical development of synthetic psilocybin, the compound naturally found in psilocybin mushrooms.
Arcadia Medicine, a San Francisco-based biotech startup developing MDMA-like empathogens, this month closed roughly $9.25 million in seed financing and won FDA clearance to begin human...
Drug Science and University College London (UCL) are joining forces in a new collaboration that seeks to address concerns over the therapy component of MDMA-assisted psychotherapy...
On August 9 the U.S
Awakn Life Sciences has entered into a new collaboration with Graft Polymer to advance its New Chemical Entity (NCE) programme, developing novel molecules for innovative addiction...
Last month, the Dutch State Commission on MDMA released its report advising the Government to allow access to MDMA-Assisted Therapy (MDMA-AT) for people living with PTSD.
A new study from MedUni Vienna has identified three new variants of MDMA as promising alternatives for safer use in a controlled psychotherapeutic setting.
An advisory body to the U.S
An emerging body of evidence is showing psychedelics as promising treatments for mental health conditions, and psychiatry needs to be prepared for their arrival, say researchers.
Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses.
